You are here

biosimilars

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

FDA approves latest Humira near-copy, as dozens of biosimilars head for market

Pharmaforum

Flag link:

DEAL WATCH: Biosimilars, Biosimilars and More Biosimilars

DEAL WATCH: Biosimilars, Biosimilars and More Biosimilars

Big Molecule Watch

Samsung Bioepis

Flag link:

Roche escapes lawsuit claiming it illegally quashed Biocad's biosimilar hopes

Roche escapes lawsuit claiming it illegally quashed Biocad's biosimilar hopes

Fierce Pharma

Flag link:

Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S.

Fierce Pharma

Teva Pharmaceutical

Flag link:

Biogen signs marketing deal for two ophthalmology biosimilars

Biogen signs marketing deal for two ophthalmology biosimilars

Pharmaforum

Samsung Bioepis

Flag link:

Biogen ups investment in biosimilars

Biogen ups investment in biosimilars

Marketwatch

Samsung Bioepis

Flag link:

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

It took a 3-year struggle, but Novartis finally gets a green light on their copycat to Amgen's big blockbuster

Endpoints

Flag link:

Under copycat attack, Amgen punches back with its own biosimilars

Under copycat attack, Amgen punches back with its own biosimilars

Fierce Pharma

Flag link:

New Study Finds Wider Adoption of Biosimilars Could Save States and Taxpayers Billions

New Study Finds Wider Adoption of Biosimilars Could Save States and Taxpayers Billions

BioSpace

Flag link:

Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress

Samsung Bioepis announces phase 3 results of SB8, Bevacizumab biosimilar candidate, at ESMO 2019 Congress

Pharmaceutical Business Review

Samsung Bioepis

clinical trials

non-small cell lung cancer

Flag link:

In U.S. Biosimilars Run Into More Roadblocks

In U.S. Biosimilars Run Into More Roadblocks

Forbes

drug development

Flag link:

We Shouldn’t Give Up on Biosimilars—And Here Are the Data to Prove it

We Shouldn’t Give Up on Biosimilars—And Here Are the Data to Prove it

Drug Channels

Flag link:

Celltrion taps Lonza to produce some of its Remicade biosimilar

Celltrion taps Lonza to produce some of its Remicade biosimilar

Biopharma Dive

Flag link:

Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilar

Pharmaforum

Flag link:

Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet

Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet

Xconomy

Flag link:

Don't give up yet on biosimilars, Gottlieb says. Congress could give them a boost

Don't give up yet on biosimilars, Gottlieb says. Congress could give them a boost

Fierce Pharma

Flag link:

Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study

Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study

Endpoints

Flag link:

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe

Pharmaforum

Flag link:

Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

Amgen biosimilar debut boosted by UnitedHealthcare coverage switch

Biopharma Dive

UnitedHealthcare

Flag link:

Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi

Novartis’ Sandoz to appeal US district court ruling on biosimilar Erelzi

Pharmaceutical Business Review

Flag link:

Pages